debra
haw
n
shanrong
shi
n
david
j
dabb
clive
r
taylor
n
richard
j
cote
c
h
p
e
r
technic
consider
limit
antigen
retriev
although
public
pathologist
long
recogn
fallibl
result
object
mean
valid
morpholog
judgment
sought
stain
use
histochem
method
valu
accentu
morpholog
featur
provid
object
evid
lineag
biolog
potenti
cell
object
immunohistochemistri
use
anti
bodi
identifi
antigen
increas
specif
stain
tissu
react
immuno
histolog
transform
surgic
patholog
highli
subject
disciplin
much
object
scienc
still
take
advantag
light
microscop
standard
morpholog
practic
immunohistochemistri
name
impli
com
binat
histolog
immunolog
result
tech
niqu
power
tool
enabl
pathologist
detect
whether
particular
antigen
present
within
given
cell
also
allow
identif
micro
anatom
cellular
locat
antigen
abil
permit
lineag
cell
popul
identifi
import
consider
confront
poorli
differenti
neoplasm
undetermin
origin
tech
niqu
also
use
defin
distinct
popul
cell
within
lineag
defin
function
differ
addit
techniqu
preserv
histolog
archi
tectur
enabl
pathologist
confirm
posit
cell
cell
question
confirm
possibl
molecular
method
revers
tran
scriptas
polymeras
chain
reaction
standard
flow
cy
tometri
method
immunohistochemistri
use
varieti
disciplin
studi
wide
rang
question
chapter
discuss
applic
technolog
surgic
patholog
immunohistochemistri
profound
fun
dament
impact
practic
patholog
immunohistochemistri
potenti
transform
sur
gical
patholog
subject
art
object
scienc
base
recognit
cell
microscop
method
although
potenti
result
almost
univers
use
immunohistochemistri
produc
uniformli
high
standard
practic
therefor
certain
technic
consider
must
born
mind
ensur
accu
raci
result
selfevid
qualiti
immuno
histochem
stain
depend
integr
antibodyantigen
interact
extent
relev
antigen
preserv
tissu
fixat
process
high
degre
variabl
way
tissu
initi
prepar
variat
includ
differ
fix
use
amount
age
ph
fix
long
tissu
sat
unfix
place
fix
thick
tissu
first
place
fix
time
tissu
left
fix
variabl
may
alter
result
routin
hematoxylineosin
h
e
stain
signific
degre
lead
wide
discrep
result
come
immunohistochemistri
variabl
alway
predict
remedi
mitig
great
extent
advent
success
rel
simpl
antigen
retriev
method
discuss
later
addit
variabl
tissu
fixat
laboratori
test
reagent
techniqu
use
must
optim
thoroughli
valid
ensur
con
sistent
reliabl
clinic
meaning
result
develop
immunohistochem
protocol
impor
tant
laboratori
perform
test
valid
everi
reagent
use
valid
includ
determin
specif
optim
work
dilut
primari
antibodi
secondari
antibodi
link
antibodi
label
reagent
substrat
repeat
valid
requir
new
lot
reagent
variat
origin
composit
concentr
specif
occur
among
differ
lot
even
suppli
compani
also
reput
manufactur
use
higher
standard
rigor
qualiti
control
product
better
manufactur
counter
balanc
concurr
prolifer
smaller
manu
factur
abl
produc
otherwis
acquir
market
larg
number
differ
antibodi
mono
clonal
antibodi
technolog
molecular
engin
like
addit
need
highqual
antibodi
reagent
proper
incub
time
ideal
temperatur
antibodi
must
determin
optim
buf
fere
agent
must
determin
well
need
predigest
techniqu
antigen
enhanc
procedur
premanufactur
allinclus
kit
market
attempt
simplifi
perform
immunohisto
chemistri
exampl
kit
obviat
need
individu
clinic
laboratori
valid
reagent
preoptim
work
dilut
recommend
work
protocol
provid
nevertheless
pitfal
kept
mind
work
premanufactur
kit
protocol
reagent
formul
work
prototyp
tissu
use
manufactur
may
effect
actual
tissu
test
laboratori
differ
fixat
process
protocol
may
advers
effect
result
adjust
recommend
protocol
necessari
optim
kit
indi
vidual
laboratori
effect
mean
kit
must
custom
chang
made
manufactur
protocol
requir
entir
stain
procedur
reval
idat
perform
laboratori
procedur
may
complic
fact
mani
work
dilu
tion
reagent
suppli
alreadi
critic
level
sensit
anoth
method
potenti
enhanc
consist
reproduc
autom
varieti
autom
immunostain
system
commerci
avail
theoret
advantag
system
manual
stain
techniqu
includ
improv
reproduc
facil
itat
interlaboratori
comparison
reduc
reagent
expens
increas
technician
product
automa
tion
mitig
need
thoroughli
valid
step
stain
procedur
need
evalu
everi
reagent
use
ensur
highqual
consist
result
qualiti
control
issu
appli
manual
stain
appli
autom
system
manual
stain
import
complet
reevalu
perform
departur
valid
protocol
auto
mation
guarante
optim
result
final
auto
mation
replac
pathologist
must
choos
appropri
antibodi
interpret
final
result
grow
need
abl
quantifi
immunohi
tochem
stain
result
probabl
best
accom
plish
autom
imag
analysi
current
system
includ
autom
cellular
imag
system
ii
aci
ii
clarient
aliso
viejo
calif
abil
assess
marker
posit
term
percentag
posit
intens
stain
abil
quantifi
marker
precis
especi
import
identif
target
therapi
one
exampl
protein
express
immunohistochemistri
compar
gene
amplif
fluoresc
situ
hybrid
use
routin
manual
method
assist
digit
microscop
accuraci
reli
abil
improv
digit
microscop
use
precis
quantif
hormon
receptor
may
also
import
evid
patient
high
level
hormon
receptor
addit
cyto
toxic
chemotherapi
deleteri
effect
outcom
anoth
excit
develop
field
autom
cellular
imag
spectral
imag
technolog
allow
multipl
marker
assess
slideeven
singl
cell
comput
softwar
isol
singl
chromogen
chromogen
present
base
emiss
spectrum
autom
cellular
imag
provid
greater
object
reproduc
thu
minim
interobserv
discrep
immunohistochem
test
perform
interpret
absenc
appropri
control
valueless
even
danger
minim
control
includ
tissu
known
express
particular
antigen
interest
pro
cess
manner
analog
unknown
tissu
posit
control
second
section
test
specimen
primari
antibodi
replac
either
diluent
better
irrelev
antibodi
isotyp
speci
concentra
tion
neg
control
posit
control
cell
expect
express
antigen
show
positiv
iti
cell
structur
element
nega
tive
neg
control
specif
stain
sausag
techniqu
sampl
multipl
tissu
gather
singl
tissu
block
use
control
method
control
perform
varieti
purpos
addi
tion
indic
whether
reaction
occur
essenti
judg
natur
reaction
vast
array
immunohistochem
test
judg
posit
neg
result
intens
localiza
tion
result
good
exampl
hormon
receptor
analysi
breast
cancer
immunohistochemistri
result
never
interpret
absenc
known
posit
result
assess
qualiti
quantiti
reaction
essenti
interpret
result
immunohistochem
stain
provinc
surgic
pathologist
best
accom
plish
pathologist
appropri
level
experi
morpholog
aspect
diagnosi
also
regard
immunohistochem
find
area
patholog
experi
matter
pathol
ogist
littl
experi
immunohistochemistri
run
differ
test
week
month
obtain
differ
result
pathologist
per
form
interpret
immunohistochem
test
daili
basi
impact
immunohistochemistri
surgic
patholog
increas
differ
becom
profound
describ
previous
mani
factor
influenc
result
factor
must
consid
pathol
ogist
interpret
find
neg
weak
unin
terpret
result
lead
repetit
test
use
antigen
retriev
one
measur
antigen
preserv
test
express
intermedi
filament
vimentin
fixationsensit
protein
typi
calli
express
vascular
connect
compon
techniqu
often
serv
intern
indic
con
servat
loss
antigen
test
result
may
also
affect
technic
artifact
natur
tissu
studi
instanc
tumor
cell
crush
fals
posit
nonspecif
stain
may
encount
non
viabl
area
tissu
necrot
tumor
may
also
sourc
falseposit
result
attribut
part
leakag
serum
protein
eg
immunoglobulin
subcellular
distribut
immunoreact
critic
interpreta
tion
immunohistochem
result
exampl
show
membran
stain
wherea
antibodi
estrogen
progesteron
receptor
produc
nuclear
stain
ing
unexpect
stain
pattern
observ
antibodi
result
discount
interpret
result
effect
pathologist
must
extens
knowledg
stain
pattern
primari
antibod
i
consider
includ
detail
knowledg
tissu
specif
subcellular
local
antigen
awar
technic
variabl
lab
oratori
perform
immunohistochem
stain
establish
written
criteria
determin
report
ing
posit
neg
find
immunohisto
chemic
stain
particular
refer
stain
expect
produc
cell
surfac
membran
cytoplasm
nuclear
extracellular
stain
although
seem
obviou
often
overlook
stain
record
posit
occur
expect
cellular
tissu
locat
food
drug
administr
increas
attent
reagent
use
immunohistochemistri
undoubt
edli
contribut
improv
qualiti
highli
recommend
laboratori
perform
di
g
nostic
immunohistochemistri
particip
colleg
american
pathologist
certif
program
includ
checklist
essenti
element
requir
success
immunostain
program
regard
staff
qualif
nation
societi
histotechnologist
focus
effort
continu
educ
certifi
cation
program
technologist
perform
immunohi
tochem
stain
feder
law
requir
high
degre
test
valida
tion
unit
state
laboratori
perform
immu
nohistochemistri
requir
clinic
laboratori
improv
amend
valid
perfor
manc
test
reagent
accuraci
specif
sensi
tiviti
precis
first
test
procedur
optim
describ
earlier
perform
expecta
tion
establish
valid
process
analyt
multipl
slide
known
patholog
gener
repres
case
evalu
optim
procedur
assess
accuraci
diagnost
stain
sensit
signal
reproduc
valid
meet
specif
must
sign
qualifi
individu
document
maintain
laboratori
qualiti
control
profici
test
must
perform
monitor
perform
although
immunohistochemistri
extrem
valuabl
techniqu
experienc
hand
limit
must
recogn
use
maximum
potenti
although
immunohistochemistri
object
routin
morpholog
examin
experi
pathologist
assess
slide
critic
firm
stand
principl
immunohistochem
stain
necessari
report
pathologist
must
equip
deal
unexpect
conflict
result
inevit
occur
evalu
immunohistochem
slide
properli
pathologist
must
firm
stand
limit
antibodi
term
technic
aspect
well
inher
specif
sensi
tiviti
expect
subcellular
locat
advent
refin
hybridoma
techniqu
product
monoclon
antibodi
produc
larg
number
avail
antibodi
often
newli
devel
ope
antibodi
hail
exquisit
specif
time
howev
found
consider
less
specif
initi
hope
gener
antigen
anti
bodi
detect
wider
distribut
expect
fact
negat
use
antibodi
que
tion
may
mean
panel
antibodi
must
use
conjunct
standard
morpholog
featur
clinic
histori
mani
studi
shown
loss
antigen
occur
cut
paraffin
section
store
vari
length
time
among
antibodi
studi
advers
affect
storag
includ
factor
viiirel
antigen
estrogen
receptor
androgen
receptor
mani
case
use
care
select
test
antigen
retriev
techniqu
compens
loss
formalin
wide
use
fix
surgic
pathol
ogi
crosslink
protein
essenti
featur
formalin
fixat
crosslink
interfer
antigen
abil
react
primari
antibodi
antigen
retriev
techniqu
develop
techniqu
heatinduc
modif
protein
con
format
allow
antigen
access
chemic
reaction
case
antibodi
bind
hydrolysi
crosslink
result
formalin
fixat
probabl
play
major
role
modif
process
applic
antigen
retriev
section
deriv
formalinfix
paraffinembed
block
produc
consist
result
accept
qualiti
although
anti
gen
remain
undetect
even
antigen
retriev
perform
antigen
retriev
method
revolut
ize
immunohistochemistri
becom
standard
part
diagnost
immunohistochemistri
surgic
pathol
ogi
method
result
higher
sensit
consist
antibodi
reactiv
antigen
retriev
technolog
led
prolifer
protocol
may
produc
differ
result
differ
laboratori
success
applic
method
allow
detect
antigen
previous
undetect
paraffin
sec
tion
render
much
earli
literatur
prior
obsolet
fact
continu
escap
notic
practic
pathologist
lead
error
interpret
fig
recogn
two
major
factor
influenc
effect
antigen
retriev
condit
heat
take
place
ph
valu
buffer
solut
use
heat
process
critic
factor
combin
temperatur
durat
heat
revers
correl
base
two
factor
heat
condit
buffer
ph
test
batteri
approach
develop
establish
optim
antigen
retriev
protocol
immunostain
archiv
paraffinembed
tissu
section
typic
test
batteri
consist
nine
serial
section
specimen
known
express
antigen
studi
section
evalu
buffer
three
differ
ph
valu
eg
ph
three
heat
condit
eg
variou
length
time
compar
heat
versu
time
schedul
best
result
select
optim
retriev
condit
antigen
event
satisfactori
result
obtain
variat
may
explor
includ
dif
ferent
buffer
solut
less
vigor
heat
method
protocol
antigen
retriev
differ
effect
retriev
certain
antigen
singl
univers
effect
retriev
method
exist
mani
laboratori
use
one
method
differ
anti
bodi
antigen
combin
overal
citrat
buffer
ph
broadest
applic
widest
rang
antigen
although
sever
studi
demonstr
use
higher
ph
retriev
solut
yield
satisfac
tori
result
retriev
solut
lower
ph
valu
tri
tromethamin
buffer
ph
edta
ethyl
enediaminetetraacet
acid
naoh
solut
ph
effect
certain
special
situat
select
heat
method
water
bath
steamer
microwav
pre
sure
cooker
autoclav
influenc
custom
avail
immunohistochemistri
becom
integr
essen
tial
part
surgic
patholog
appli
defin
tumor
origin
establish
prognosi
determin
treatment
respons
textbook
role
immunohistochem
istri
defin
origin
prognosi
treatment
respons
tumor
discuss
chapter
devot
specif
organ
system
therefor
full
discuss
provid
evalu
tumor
unknown
origin
fall
particular
organ
system
discuss
chapter
tumor
classifi
often
tissu
origin
eg
breast
colon
prostat
histogenet
eg
tissu
epitheli
mesenchym
neural
origin
tumor
stage
accur
proper
therapi
administ
without
classif
although
accept
fairli
reproduc
criteria
exist
morpholog
diagnosi
tumor
inher
subject
morpholog
evalu
well
recogn
morpholog
featur
often
overlap
among
differ
entiti
one
diseas
present
myriad
histolog
pictur
tumor
classifi
correctli
routin
histolog
techniqu
clinic
situat
clear
eg
breast
mass
howev
import
subset
tumor
defi
morpholog
interpret
magnitud
problem
substanti
diagnosi
metastat
cancer
unknown
primari
site
eighth
common
cancer
diagnosi
may
repres
cancer
larg
hospit
much
common
diagnosi
tumor
uncertain
origin
occur
tumor
first
identifi
metastat
site
primari
site
appar
tumor
poorli
differenti
specif
morpholog
featur
identifi
morpholog
appear
tumor
compat
one
distinct
tissu
eg
epitheli
versu
lymphoid
origin
histogenesi
tumor
clear
eg
adenocarcinoma
primari
site
que
tion
distinct
import
consequ
patient
immunohistochem
test
perform
defin
object
mind
result
singl
immuno
histochem
procedur
mislead
variabl
stain
procedur
also
unanticip
pattern
reactiv
certain
antibodi
although
myriad
antibodi
avail
choic
particular
case
judici
design
address
diagnost
possibl
use
antibodi
rare
provid
suffici
inform
support
specif
diagnosi
produc
mislead
inform
anti
bodi
select
basi
abil
affirm
exclud
consider
differenti
diagno
si
socal
problemori
approach
base
select
appropri
panel
antibodi
select
antibodi
factor
consid
includ
clinic
histori
morpholog
featur
tumor
result
test
may
per
form
includ
serolog
radiograph
test
pathol
ogist
find
guidanc
literatur
special
textbook
address
use
immunohisto
chemistri
rapidli
evolv
field
limit
antibodi
panel
year
ago
inadequ
deal
tumor
unknown
uncertain
primari
site
today
mind
panel
present
must
con
sider
elementari
guid
evalu
tumor
uncertain
origin
immuno
histochemistri
certain
basic
guidelin
interpret
must
kept
mind
posit
stain
reaction
gener
alli
help
neg
one
lack
immunoreact
may
repres
technic
problem
tissu
way
fix
discuss
earlier
poorli
differenti
tumor
less
like
express
tissu
differenti
antigen
often
stain
variat
within
tumor
extens
vari
ation
stain
pattern
may
seen
primari
tumor
metastat
focu
import
final
diagnosi
never
depend
immunohistochemistri
alon
must
made
use
clinic
serolog
radiograph
morpholog
epidemiolog
data
avail
abl
techniqu
assess
specif
dna
alter
becom
increasingli
import
adjunct
patholog
evalu
although
immuno
histochem
evalu
essenti
one
mani
tool
must
use
evalu
patholog
process
applic
primari
panel
antibodi
character
tumor
histogenesi
epitheli
mesenchym
neural
hematopoiet
often
first
step
panel
establish
addit
antibodi
use
identifi
tumor
type
specif
includ
first
tier
would
antibodi
pankeratin
vimentin
protein
neuronspecif
enolas
nse
common
leukocyt
antigen
differenti
epith
lial
mesenchym
melanomat
neural
lymphoid
malign
tabl
fig
express
intermedi
filament
protein
function
support
cytoskeleton
normal
neo
plastic
cell
extrem
use
initi
assess
tumor
unknown
primari
origin
five
major
class
intermedi
filament
base
protein
compo
sition
cellular
distribut
cytokeratin
vimentin
desmin
neurofila
glial
fibrillari
acid
protein
gfap
neoplasm
show
predomin
expr
sion
one
intermedi
filament
carci
noma
usual
express
cytokeratin
sarcoma
melanoma
cytokeratin
present
almost
epitheli
cell
highli
sensit
marker
carcinoma
gener
sens
malign
cell
express
keratin
posit
indic
epitheli
origin
antibodi
keratin
also
extrem
use
marker
occult
metastas
micro
metastas
peripher
blood
bone
marrow
lymph
node
discuss
later
differ
subtyp
cytokeratin
found
human
epitheli
cell
subtyp
distin
guishabl
molecular
weight
isoelectr
ph
monoclon
antibodi
specif
mani
subtyp
develop
carcinoma
differ
type
tend
express
characterist
keratin
profil
gener
correl
complex
epithelium
tumor
deriv
complex
keratin
subunit
express
lowmolecularweight
non
squamou
keratin
appear
earli
develop
pre
domin
tumor
deriv
simpl
nonstratifi
epithelium
eg
ductal
carcinoma
breast
gastroin
testin
adenocarcinoma
highmolecularweight
squa
mou
keratin
appear
complex
stratifi
epithelium
predomin
tumor
deriv
stratifi
epith
lium
eg
squamou
cell
carcinoma
tumor
deriv
pseudostratifi
columnar
epith
lium
contain
mixtur
high
lowmolecularweight
keratin
predomin
latter
instanc
especi
extrem
poorli
differenti
tumor
tumor
cell
may
express
keratin
reactiv
tumor
uncertain
primari
site
defin
epitheli
either
immunohistochemistri
morphol
ogi
import
attempt
defin
specif
origin
present
problem
exampl
patient
prior
histori
breast
carcinoma
present
lung
mass
biopsi
adenocarcinoma
determin
whether
lung
mass
repres
primari
pulmonari
tumor
metastasi
breast
enorm
cons
quenc
term
patient
outcom
choic
specif
treatment
although
immunohistochem
evalu
primari
epitheli
tumor
problemat
advanc
made
monoclon
antibodi
keratin
subtyp
may
help
determin
origin
certain
poorli
differenti
ate
neoplasm
hepatocellular
carcinoma
posit
cam
neg
distinguish
bile
duct
carcinoma
adenocarcinoma
metastat
liver
posit
particular
differenti
express
cytokeratin
extrem
use
character
epitheli
neo
plasm
fig
pattern
absolut
use
guid
establish
origin
cytokeratin
receiv
consider
attent
recent
found
posit
major
squamou
cell
carcinoma
basal
cell
carci
noma
thymoma
salivari
gland
tumor
biphas
malign
mesothelioma
subset
endometri
adenocarcinoma
transit
cell
carcinoma
pancr
atic
adenocarcinoma
rare
posit
adeno
carcinoma
lung
therefor
use
distinguish
malign
mesothelioma
pulmonari
ade
nocarcinoma
addit
frequent
seen
squamou
cell
carcinoma
transit
cell
carcinoma
wherea
mesothelioma
uniformli
neg
fore
posit
immunostain
highli
predict
primari
tumor
squamou
epitheli
origin
also
known
immunoreact
basal
cell
nuclei
benign
prostat
gland
marker
use
distinguish
prostat
cancer
benign
mimic
increas
array
tissuespecif
marker
prostatespecif
antigen
psa
thyroglobulin
well
tissueassoci
marker
mammaglobin
breast
epithelium
ovari
uroplakin
urothelium
synaptophysin
neuroendocrin
lesion
fig
tabl
summar
mani
tissueassoci
antibodi
import
keep
mind
pattern
antigen
coexpress
lead
erron
assess
also
mention
earlier
poorli
differenti
neoplasm
less
like
express
tissuespecif
associ
antigen
nevertheless
specif
origin
epitheli
neoplasm
uncertain
primari
site
elucid
increas
proport
case
care
evalu
morphol
ogi
clinic
data
antigen
express
lymphoma
often
present
morpholog
undifferenti
ate
malign
neoplasm
larg
cell
lymphoma
may
difficult
differenti
carcinoma
melanoma
ana
plastic
larg
cell
lymphoma
occasion
react
anti
bodi
keratin
epitheli
membran
antigen
similarli
small
cell
lymphoma
often
resembl
tumor
small
cell
undifferenti
carcinoma
immunohistochemistri
invalu
classifi
tumor
lymphoid
origin
immunohistochemistri
also
use
wide
aid
subclassif
nonhodgkin
lymphoma
discuss
detail
chapter
anoth
import
applic
immunohistochemistri
phe
notyp
lesion
determin
immunoglobulin
lightchain
express
one
distinguish
malig
nant
benign
lymphoid
prolifer
demonstr
lightchain
heavychain
restrict
excel
screen
marker
determin
whether
tumor
lymphoid
origin
stain
charac
terist
membran
neoplasm
lymphoid
origin
may
express
rare
nonlymphoid
neo
plasm
may
show
cytoplasm
stain
specif
lymphoid
marker
mark
cell
mark
b
cell
may
delin
lesion
immunohistochemistri
also
use
case
hodgkin
diseas
marker
use
identi
fy
reedsternberg
cell
includ
figur
illustr
algorithm
approach
immunohistochem
diagnosi
malign
lymphoma
melanoma
typic
alway
neg
cytokeratin
posit
vimentin
protein
sensit
marker
melanoma
occur
almost
case
nuclear
pattern
see
fig
specif
melanoma
howev
seen
varieti
lesion
includ
langerhan
histiocyt
mani
sarcoma
certain
carcinoma
posit
immunoreact
melan
tyrosinas
much
specif
marker
melanoma
melanocyt
confirm
diagnosi
topic
discuss
detail
chapter
diagnosi
sarcoma
worth
consid
spindl
cell
neoplasm
express
vimentin
keratin
immunohistochem
analysi
delin
specif
type
sarcoma
myogen
fibrohistio
cytic
tumor
tumor
neural
differenti
va
cular
sarcoma
differenti
soft
tissu
tumor
immunohistochemistri
discuss
chapter
major
subtyp
describ
briefli
myogen
sarcoma
react
antibodi
muscl
specif
actin
desmin
antibodi
smooth
muscl
actin
show
preferenti
reactiv
leio
myosarcoma
alveolar
soft
part
sarcoma
typic
coex
press
vimentin
desmin
tumor
deriv
skelet
muscl
often
contain
myoglobin
posit
immunoreact
musclespecif
actin
desmin
myoglobin
indic
tumor
question
may
rhabdomyosarcoma
fibrohistiocyt
tumor
includ
malign
fibrou
tiocytoma
common
form
soft
tissu
sarcoma
adult
malign
fibrou
histiocytoma
react
vimen
tin
lack
signific
reactiv
keratin
lesion
neurogen
tumor
includ
malign
peripher
nerv
sheath
tumor
schwannoma
posit
antibodi
protein
myelin
basic
protein
although
benign
neurogen
tumor
schwannoma
neurofibroma
contain
less
half
malign
peripher
nerv
sheath
tumor
contain
detect
protein
normal
neoplast
vessel
identifi
endotheli
marker
factor
viiirel
antigen
ulex
europaeu
lectin
antibodi
factor
viiirel
antigen
react
endotheli
cell
megakaryo
cyte
specif
ulex
europaeu
tdt
marker
endotheli
cell
includ
sensit
less
specif
factor
viii
tumor
consid
differenti
diag
nosi
anaplast
spindl
cell
tumor
includ
liposarco
ma
chondrosarcoma
osteogen
sarcoma
fibrosarcoma
synovi
sarcoma
although
certain
variant
liposar
coma
may
diagnos
histolog
criteria
alon
diagnosi
pleomorph
liposarcoma
aid
immuno
histochemistri
liposarcoma
react
vimentin
nonreact
contrast
melanoma
pattern
seen
chondrosarco
ma
osteosarcoma
react
vimentin
antibodi
socal
osteonectin
osteosarcoma
antigen
also
may
assist
diagnosi
fibrosarcoma
rare
neoplasm
express
vimentin
figur
provid
immu
nostain
pattern
characterist
anaplast
spindl
cell
tumor
cytogenet
profil
sarcoma
unknown
origin
becom
common
tumor
known
abnorm
includ
endometri
sarcoma
myeloid
sarcoma
synovi
sarcoma
ewe
sarcoma
viscer
clear
cell
sarcoma
among
other
topic
discuss
detail
chapter
neural
neuroendocrin
tumor
may
classifi
neural
tumor
neuroepitheli
tumor
neural
neoplasm
mesenchym
origin
three
categori
base
differ
predomin
intermedi
filament
found
cytoplasm
lesion
neural
tumor
usual
express
neurofila
nse
chromogranin
synapto
physin
exampl
includ
neuroblastoma
paraganglio
ma
pheochromocytoma
neuroepitheli
tumor
coexpress
keratin
neuroendocrin
marker
tumor
includ
carcinoid
merkel
cell
carcinoma
small
cell
carcinoma
neural
neoplasm
mesenchym
origin
consist
primit
neuroectoderm
tumor
ewe
sarcoma
medulloblastoma
posit
vimentin
may
express
nse
good
marker
small
cell
tumor
ewe
sarcoma
primit
neuroectoderm
tumor
peripher
neuroepitheli
tumor
identifi
antigen
nse
although
sensit
marker
neuroendocrin
tumor
lack
specif
seen
wide
varieti
tumor
type
chromogranin
synaptophysin
specif
nse
lack
sensit
chromogranin
tend
posit
betterdifferenti
neuroendocrin
tumor
less
often
posit
poorli
differenti
tumor
small
cell
carcinoma
tabl
pro
vide
immunostain
pattern
endocrin
tumor
figur
illustr
algorithm
use
distinguish
small
round
cell
tumor
gfap
express
glial
cell
seen
astrocytoma
ependymoma
medulloblastoma
oligodendroglio
ma
choroid
plexu
tumor
also
report
extracerebr
tumor
includ
pleomorph
ade
noma
salivari
gland
neurofibroma
schwanno
ma
intracerebr
tumor
gfap
expect
posit
includ
meningioma
lymphoma
cancer
result
defect
gene
structur
express
alter
chromosom
dna
structureinclud
cytogenet
chang
point
mutat
delet
amplif
transloc
dna
methylationar
identifi
increas
rate
character
defect
becom
import
compon
tumor
evalu
particularli
term
prognosi
respons
treatment
addit
genet
defect
highli
characterist
specif
tumor
type
identifi
identif
dna
alter
also
becom
increasingli
import
compon
evalu
tumor
uncertain
primari
site
molecular
genet
evalu
particularli
use
evalu
hema
topoiet
soft
tissu
tumor
recent
highli
sophist
evalu
hundr
gene
use
call
microarray
chip
technolog
use
identifi
gene
express
differ
sever
tumor
type
doubt
becom
import
compon
tumor
evalu
futur
transcript
factor
protein
involv
regul
gene
express
bind
promot
element
upstream
gene
either
facilit
inhibit
transcrip
tion
may
tissu
specif
may
present
one
tissu
type
even
socal
tissuespecif
transcript
factor
howev
usual
restrict
singl
tumor
type
exampl
includ
thyroid
transcript
found
thyroid
lung
pituitari
transcript
factor
found
placenta
well
pituitari
gland
nevertheless
use
determin
primari
site
tumor
unknown
origin
see
tabl
belong
famili
homeodomain
transcript
factor
play
role
regul
gene
express
within
thyroid
lung
diencephalon
consid
reliabl
marker
distinguish
primari
tumor
lung
includ
adenocarcinoma
nonsmal
cell
car
cinoma
neuroendocrin
small
cell
carcinoma
squamou
cell
carcinoma
thyroid
tumor
type
howev
primari
adeno
carcinoma
colon
posit
case
pattern
reactiv
nuclear
hepatocyt
hepatocel
lular
carcinoma
reportedli
show
cytoplasm
posit
homeobox
gene
encod
transcript
factor
involv
develop
intestin
epithelium
express
normal
colon
epithelium
colorect
adenocarcinoma
use
marker
iden
tifi
colorect
metastas
also
use
extra
mammari
paget
diseas
endoderm
subtyp
posit
wherea
cutan
subtyp
neg
activ
transcript
factor
member
basic
leucin
zippercycl
adenosin
monophosphaterespons
element
bind
protein
famili
transcript
factor
studi
indic
androgenregul
gene
stimul
cell
prolifer
protein
detect
immunohistochemistri
present
prostat
tumor
increas
express
highgleasonscor
diseas
tumor
refract
therapi
one
outstand
achiev
modern
medicin
abil
predict
behavior
tumor
base
specif
clinic
patholog
criteria
tumor
stage
grade
provid
gener
estim
outcom
par
ticular
patient
howev
current
clinic
patholog
stage
paramet
identifi
patient
destin
experi
relaps
whose
diseas
cure
local
therapi
alon
consider
obviou
consequ
patient
enorm
eco
nomic
implic
effort
way
identifi
enzym
oncogen
tumor
suppressor
gene
whose
presenc
absenc
may
predict
accur
biolog
behavior
tumor
studi
repres
fundament
shift
mean
tumor
behavior
defineda
chang
outcomebas
empir
analysi
ie
predict
tumor
base
done
one
focus
tumor
biolog
ie
predict
behavior
base
specif
genet
alter
immunohistochem
analysi
tumor
also
undergo
profound
shift
emphasi
although
initi
studi
focus
defin
tumor
histogenesi
goal
much
current
research
reveal
biolog
potenti
tumor
provid
scientif
basi
patient
manag
use
advanc
technolog
defin
tumor
prog
nosi
describ
detail
throughout
book
present
gener
principl
pertain
prog
nostic
evalu
tumor
import
factor
affect
outcom
patient
invas
cancer
whether
tumor
spread
either
region
region
lymph
node
system
proport
patient
evid
system
di
semin
evalu
routin
method
care
patho
logic
clinic
biochem
radiolog
evalu
develop
recurr
diseas
addit
success
adju
vant
therapi
assum
stem
abil
erad
occult
metastas
becom
clinic
evid
immunohistochemistri
commonli
use
identifi
occult
metastat
cancer
cell
bone
marrow
peripher
blood
lymph
node
patient
cancer
although
mani
initi
studi
focus
breast
cancer
tumor
organ
stomach
colon
prostat
lung
nervou
system
skin
investig
immunohistochem
method
base
abil
monoclon
antibodi
distinguish
cell
differ
histogenesi
eg
epitheli
cancer
cell
versu
hematopoiet
stromal
cell
bone
marrow
lymph
node
result
indic
possibl
identifi
occult
metastat
cancer
cell
lymph
node
bone
marrow
detect
method
presenc
cell
may
import
risk
factor
diseas
recurr
fig
wide
use
monoclon
antibodi
detect
occult
metastat
carcinoma
cell
direct
toward
epi
theliumspecif
antigen
antibodi
react
normal
hematopoiet
stromal
cell
present
bone
marrow
lymph
node
none
antibodi
use
studi
specif
cancer
react
normal
malign
epitheli
cell
use
identifi
extrins
popul
epitheli
cell
bone
marrow
lymph
node
normal
epi
thelial
element
report
sensit
immunohisto
chemistri
rang
detect
epitheli
cell
epitheli
cell
million
hematopoiet
cell
potenti
sensit
approach
detect
occult
metastasi
revers
transcriptas
polymeras
chain
reaction
rtpcr
techniqu
appli
sever
malign
use
varieti
marker
transcript
target
sinc
first
studi
smith
colleagu
mani
author
report
molecular
diagnos
lymph
node
blood
bone
marrow
cancer
patient
applic
rtpcr
region
sentinel
lymph
node
describ
number
cancer
includ
melanoma
colorect
cancer
cancer
prostat
breast
lung
mani
compar
immunocytochemicalbas
detect
rt
pcr
sensit
conclud
rtpcr
may
achiev
enhanc
detect
provid
target
marker
suffi
cientli
specif
variou
format
rtpcr
assay
also
use
detect
dissemin
tumor
cell
bone
marrow
patient
cancer
breast
colon
lung
among
other
except
organ
specif
marker
maspin
mammaglobin
breast
cancer
uroplakin
urotheli
tumor
molecular
target
use
rtpcr
assay
lack
requisit
specif
owe
illegitim
express
nontarget
hematopoiet
cell
unlik
immunohisto
chemistri
morpholog
confirm
cell
que
tion
verifi
tumor
origin
possibl
rtpcr
rtpcr
also
use
enhanc
sensit
detect
tumor
cell
peripher
blood
varieti
cancer
includ
prostat
breast
gastrointesti
nal
tract
colorect
head
neck
cancer
mela
noma
concern
nonspecif
owe
illegitim
transcript
target
gene
nontarget
hematopoiet
cell
also
appli
blood
ham
pere
use
assay
routin
clinic
diagnosi
breast
cancer
bone
marrow
singl
common
site
metastasi
patient
recurr
tumor
develop
bone
marrow
metastas
point
evolut
diseas
immunohistochemistri
show
presenc
occult
metastas
bone
marrow
approxim
patient
lowstag
diseas
sever
studi
address
clini
cal
signific
earli
metastat
cell
bone
marrow
includ
pool
analysi
patient
found
presenc
cell
independ
prognost
indic
diseasefre
sur
vival
overal
surviv
occult
metastas
bone
marrow
also
prognost
import
malign
includ
primari
nonsmal
cell
lung
cancer
esophag
gastric
cancer
colo
rectal
cancer
neuroblastoma
find
posi
tive
cell
bone
marrow
patient
colorect
cancera
tumor
rare
show
overt
metastasi
boneind
may
gener
indic
tumor
dissemin
addit
prognost
signifi
canc
occult
metastat
cell
blood
investig
peripher
blood
advantag
easier
access
bone
marrow
howev
detect
rate
con
sider
lower
bone
marrow
fact
hamper
studi
date
detect
tumor
cell
bone
marrow
blood
epitheli
cell
adhes
molecul
conjunct
immunomagnet
enrich
use
detect
circul
tumor
cell
breast
cancer
patient
circul
tumor
cell
blood
use
monitor
respons
therapi
patient
metastat
cancer
presenc
epitheli
adhes
moleculeposit
cell
initi
therapi
found
independ
prognost
factor
marker
use
patient
breast
cancer
includ
mammaglobin
epi
dermal
growth
factor
receptor
carcinoembryon
antigen
although
none
marker
entir
specif
detect
metastat
breast
cancer
although
sensit
peripher
blood
less
bone
marrow
grow
evid
detec
tion
occult
metastat
cell
peripher
blood
neg
impact
prognosi
recent
studi
found
presenc
five
tumor
cell
periph
eral
blood
patient
breast
cancer
examin
upon
initi
therapi
import
predict
outcom
peripher
blood
patient
colorect
stomach
prostat
skin
cancer
also
studi
marker
studi
colorect
cancer
includ
cytokeratin
carcinoembryon
antigen
apolipoprotein
psa
messeng
rna
mrna
commonli
use
marker
patient
prostat
cancer
tyrosinas
mrna
marker
studi
undertaken
detect
occult
lymph
node
metastas
routin
histolog
method
gener
per
form
cut
serial
section
paraffin
block
contain
lymph
node
follow
routin
stain
microscop
review
sever
studi
simpli
review
origin
histolog
slide
newer
studi
involv
cytokeratin
immunohistochemistri
one
lymph
node
sec
tion
psa
immunohistochemistri
also
use
confirm
prostat
origin
cytokeratinposit
cell
lymph
node
patient
prostat
cancer
studi
shown
deposit
tumor
detect
use
method
previous
determin
nodeneg
case
breast
cancer
convert
nodeposit
statu
review
nevil
colleagu
found
mean
convers
rate
approxim
although
virtual
studi
shown
lymph
node
metastas
overlook
surpris
disagr
prognost
import
occult
tumor
deposit
howev
wide
accept
detect
occult
lymph
node
metastas
import
predictor
outcom
patient
histolog
nodeneg
cancer
key
studi
ludwig
trial
v
occult
breast
cancer
metastas
detect
immunohistochemistri
patient
associ
significantli
poor
diseasefre
overal
surviv
postmenopaus
patient
pre
menopaus
patient
addit
studi
patient
breast
cancer
found
occult
lymph
node
metastas
predict
poorer
outcom
studi
patient
lung
prostat
colorect
cancer
suggest
occult
metastas
lymph
node
patient
may
also
predict
wors
prognosi
find
occult
bone
marrow
lymph
node
metastas
prognost
import
motiv
sever
major
clinic
trial
notabl
american
colleg
surgeon
oncolog
group
breast
cancer
lung
cancer
advent
use
sentinel
lymph
node
biopsi
tumor
surgeri
breast
cancer
melanoma
caus
physician
examin
lymph
node
sensit
techniqu
owe
limit
materi
avail
histolog
review
like
detect
occult
metastas
soon
gener
stan
dard
care
true
mani
institut
treat
larg
number
patient
cancer
cerb
protooncogen
gene
encod
protein
kd
show
homolog
epiderm
growth
factor
display
tyrosin
activ
amplif
gene
code
describ
breast
ovarian
prostat
gastric
salivari
gland
lung
colon
squamou
cell
carcinoma
express
protein
accumul
cell
membran
seen
crisp
membran
stain
cytoplasm
stain
ing
pattern
associ
protein
gene
overex
pression
although
overexpress
amplif
describ
sever
tumor
system
studi
extens
breast
overex
pression
occur
primari
breast
carcino
ma
restrict
cancer
cell
invers
associ
amplif
expr
sion
estrogen
progesteron
receptor
overexpress
also
associ
highgrad
tumor
consid
advers
prognost
indictor
patient
breast
cancer
presenc
overexpr
sion
associ
resist
tamoxifen
therapi
cmf
cyclophosphamid
methotrex
uracil
adjuv
chemotherapi
associ
increas
respons
regimen
use
highdos
doxoru
bicin
recent
studi
link
amplif
topoisomeras
gene
effect
anthracyclin
preliminari
data
suggest
coamplifica
tion
two
gene
may
identifi
subgroup
highrisk
breast
cancer
patient
might
benefit
individu
tailor
doseescal
adjuv
anthracyclin
also
assess
amplif
gene
fluoresc
situ
hybrid
epiderm
growth
factor
receptor
egfr
belong
famili
growth
factor
receptor
involv
normal
growth
gene
locat
chromosom
receptor
epiderm
growth
factor
member
receptor
tyrosin
kinas
famili
close
relat
egfr
known
involv
carci
nogen
process
cell
prolifer
apoptosi
angiogenesi
cell
motil
metastasi
express
egfr
examin
wide
varieti
tissu
mani
case
increas
express
egfr
predic
tive
tumor
progress
eg
cancer
breast
esoph
agu
adren
lung
bladder
thyroid
gastrointestin
tract
glioblastoma
multiform
addit
immunohistochem
method
fluoresc
situ
hybrid
izat
use
success
identifi
egfr
muta
tion
delet
formalinfix
paraffinembed
tissu
egfr
also
show
promis
therapeut
target
studi
way
lung
colorect
cancer
determin
use
target
egfr
anticanc
therapi
primari
characterist
tumor
suppressor
gene
encod
normal
cellular
product
involv
growth
control
allel
must
inactiv
loss
function
ie
loss
tumor
suppress
occur
well
known
retinoblastoma
rb
protein
two
best
character
rb
gene
thought
involv
growth
control
regul
transcript
rb
gene
locat
chromosom
dy
function
number
type
cancer
normal
func
tion
prevent
replic
damag
dna
prevent
cell
replic
bind
inhibit
transcript
factor
retinoblastoma
protein
prb
activ
dephosphoryl
inacti
vate
phosphoryl
alter
gene
describ
mani
human
tumor
includ
retinoblastoma
osteosarcoma
sarcoma
leukemia
lymphoma
certain
carcinoma
includ
breast
lung
prostat
bladder
kidney
testicular
carcinoma
gene
alter
associ
advanc
tumor
grade
stage
varieti
tumor
alter
rb
gene
correl
loss
express
prb
determin
immunohistochemistri
assess
rb
gene
loss
immunohistochemistri
base
loss
detect
nuclear
stain
prb
grow
evid
gene
alter
may
identifi
tumor
higher
risk
develop
metastas
loss
heterozygos
muta
tion
delet
rb
gene
usual
result
loss
prb
express
regard
indic
loss
prb
function
human
tumor
addit
loss
prb
express
aberrantli
high
prb
express
indi
cate
loss
prb
function
bladder
tumor
compar
moder
prb
express
shown
tumor
prb
overexpress
demonstr
prb
hyper
phosphoryl
mediat
part
loss
expr
sion
overexpress
cyclin
gene
locat
chromosom
protein
express
normal
cell
halflif
normal
protein
short
minut
accumul
level
high
enough
detect
standard
immunohistochem
techniqu
mutant
protein
contrast
extend
halflif
accumul
readili
detect
cell
nucleu
mutat
indic
posit
stain
alter
gene
extrem
common
human
cancer
describ
bladder
colon
lung
breast
carcino
ma
astrocytoma
leukemia
sarcoma
mesothelio
ma
import
alter
human
cancer
eas
detect
mutat
molecular
immunohistochem
method
alter
ation
focu
intens
examin
rb
alter
alter
associ
tumor
high
histolog
grade
high
prolif
index
grow
evid
least
type
tumor
alter
identifi
patient
shorter
diseasefre
interv
poorer
overal
surviv
cyclindepend
kinas
inhibitor
famili
cell
cycl
regul
primari
function
seem
format
stabl
complex
cyclindepend
kinas
protein
subsequ
inhibit
cell
cycl
complex
inactiv
catalyt
oper
unit
among
well
known
clinic
relev
member
wafcipkip
famili
cyclindepend
kinas
inhibitor
probabl
best
character
act
regul
epitheli
carcinogenesi
differen
tiation
thought
play
import
role
tumor
suppress
regul
cell
cycl
progress
dna
rep
licat
dna
repair
protein
express
studi
varieti
tumor
type
includ
breast
gastric
ovari
colorect
bladder
carcinoma
alter
protein
express
assess
immunohistochem
method
associ
higher
tumor
grade
wors
prognosi
patient
bladder
cancer
inhibitor
involv
regul
cell
cycl
g
transit
ultim
inhibi
tion
prb
phosphoryl
mutat
human
gene
appear
rare
loss
express
associ
colon
breast
prostat
gastric
cancer
progress
also
known
tumor
sup
pressor
protein
encod
locu
chro
mosom
one
frequent
site
genet
loss
human
cancer
numer
studi
found
abnorm
protein
varieti
tumor
type
includ
melanoma
glioma
esophag
pancreat
lung
bladder
carcinoma
certain
type
lympho
ma
addit
known
regul
rb
immunohistochem
express
prb
invers
correl
varieti
tumor
combin
effect
prb
known
individu
prb
ind
pendent
predictor
time
recurr
overal
sur
vival
patient
bladder
cancer
effort
therefor
made
examin
determin
com
binat
one
studi
patient
analyz
accord
ing
whether
none
one
two
three
marker
posit
surviv
rate
respect
data
suggest
alter
prb
act
cooper
synergist
way
promot
bladder
cancer
progress
cyclin
play
key
role
regul
g
transit
phase
cell
cycl
link
number
differ
cancer
includ
colorect
esop
h
ageal
gastric
lung
head
neck
pancreat
cancer
although
major
purpos
molecular
assess
cancer
better
understand
risk
diseas
progr
sion
advanc
technolog
also
use
stand
specif
pattern
respons
resist
therapeut
regimen
tradit
mean
determin
appropri
system
treatment
gener
involv
histo
genic
classif
long
recogn
howev
respons
hormon
therapi
predict
spe
cific
molecular
determin
eg
express
estrogen
progesteron
receptor
breast
cancer
reproduct
organ
tumor
aris
breast
prostat
endometrium
ovari
known
regul
steroid
sex
hor
mone
estrogen
androgen
discov
remov
sourc
hormon
control
tumor
growth
oophorectomi
orchiectomi
chemic
method
sometim
result
dramat
tumor
remiss
growth
regul
found
associ
amount
specif
hormon
receptor
tumor
express
high
level
receptor
tend
respond
well
hormon
ablat
wherea
receptor
tend
respond
type
therapi
accur
method
determin
presenc
absenc
hormon
recep
tor
essenti
determin
best
method
treatment
avail
monoclon
antibodi
estrogen
progesteron
androgen
receptor
made
immuno
histochem
detect
hormon
receptor
statu
current
method
choic
immunohistochem
method
perform
formalinfix
paraffin
embed
tissu
cytolog
specimen
immunohi
tochem
antireceptor
assay
allow
one
predict
breast
cancer
respons
hormon
treatment
tumor
express
estrogen
progesteron
receptor
low
probabl
respond
hormon
manipul
wherea
estrogen
receptorand
progesteron
receptorpo
itiv
tumor
high
probabl
respond
treatment
mani
practition
believ
relev
result
hormon
receptor
breast
cancer
posit
neg
howev
investig
shown
level
hormon
receptor
import
well
although
proport
patient
low
level
hormon
receptor
respond
hormon
therapi
benefit
addit
system
cytotox
chemoth
api
contrast
patient
high
level
hormon
receptor
addit
cytotox
chemotherapi
del
eteri
effect
outcom
recent
attent
focus
express
estrogen
receptor
subtyp
variou
isoform
subtyp
found
estrogen
receptor
tumor
express
signific
level
estrogen
receptor
express
level
differ
level
estrogen
receptor
tumor
therefor
two
estrogen
receptor
isoform
may
potenti
molecular
target
design
chemopr
ventiv
drug
treat
estrogen
receptor
breast
cancer
pglycoprotein
transmembran
protein
kd
associ
intrins
acquir
resi
tanc
certain
chemotherapeut
agent
particularli
anthracyclin
vinca
alkaloid
pglycoprotein
also
may
play
role
tumor
progress
associ
blood
vessel
invas
lymph
node
metastas
tumor
inher
express
pglycoprotein
wherea
tumor
acquir
express
exposur
certain
chemotherapeut
agent
overexpress
associ
ate
failur
chemotherapi
predictor
respons
specif
form
chemo
therapi
explor
prevail
view
alter
result
chemoresist
phe
notyp
view
base
bodi
evid
show
wildtyp
requir
entranc
apop
totic
pathway
g
sphase
transit
chemotherapi
work
induct
apoptosi
alter
may
result
resist
agent
conduct
clinic
trial
concern
role
predict
progress
respons
patient
bladder
cancer
also
possibl
may
promot
chemo
resist
mechan
induct
multidrug
resist
gene
tumor
alter
confer
increas
select
che
mosensit
combin
agent
differ
action
eg
dna
damag
versu
inhibit
g
check
point
may
synergist
effect
tumor
cell
kill
find
import
implic
design
new
combin
chemotherapi
regimen
express
thymidyl
synthas
colorect
tumor
predict
resist
common
type
system
chemotherapi
use
diseas
cil
mention
earlier
overexpress
breast
cancer
predict
resist
hormon
therapi
estrogen
receptorposit
tumor
resist
type
chemotherapi
increas
sensit
doxorubicinbas
regimen
egfr
specif
target
antibodydirect
therapi
case
seem
tumor
overexpress
target
like
respond
therapi
case
colorect
cancer
therapi
direct
egfr
appear
work
tumor
wildtyp
kra
tumor
mutant
kra
respond
egfr
therapi
similar
find
seen
lung
cancer
abil
predict
specif
respons
individu
tumor
chemotherapeut
agent
profound
effect
treatment
decis
patient
cancer
difficult
envis
day
drug
select
base
resist
pattern
individu
tumor
specif
agent
treatment
decis
becom
less
organ
base
better
reflect
biolog
tumor
tradit
stain
avail
surgic
pathologist
identifi
infecti
organ
tissu
section
consist
gram
stain
variat
acidfast
stain
period
acidschiff
silver
stain
wide
rang
immu
nohistochem
situ
hybrid
techniqu
avail
detect
specif
type
organ
within
fix
paraffin
section
although
cultur
tech
niqu
remain
import
method
diagnos
infect
immunohistochem
method
effect
even
superior
cultur
routin
h
e
method
detect
certain
infecti
organ
cytomegaloviru
fig
mycobacteria
toxoplasma
pneumocysti
carinii
histoplasma
capsulatum
helicobact
pylori
human
papillomaviru
tabl
summar
infecti
agent
iden
tifi
immunohistochemistri
